Customized cell-penetrating peptide (CPP)-conjugated lipid nanoparticle (LNP) development services for cytosolic delivery research, endosomal escape evaluation, CPP sequence screening, surface density optimization, and payload-compatible formulation development.
Cell-penetrating peptide-conjugated lipid nanoparticles are LNP delivery systems with short membrane-active peptides displayed on the particle surface. These peptides promote contact with the cell membrane, increase particle internalization, and in favorable designs help the payload move from the endosomal compartment into the cytosol. Because many LNP programs already achieve acceptable cellular association but still show limited functional delivery, CPP modification is often explored as a way to address the intracellular step rather than the tissue-level step.
BOC Sciences supports pharmaceutical, biotechnology, and academic research teams developing peptide-functionalized lipid nanoparticles with CPP surface display. Our work covers CPP sequence selection and custom design, peptide-lipid conjugate preparation, surface incorporation route selection, ligand density screening, core formulation balancing, physicochemical characterization, and in vitro uptake, endosomal escape, and functional delivery evaluation.
CPP-Modified Lipid Nanoparticle Structure Illustration
BOC Sciences supports the full CPP-LNP development workflow, from peptide sequence selection and conjugate preparation to LNP surface engineering, characterization, and intracellular delivery evaluation.
We help select or design the CPP module according to the payload, the cell model, and the delivery question. The peptide is then prepared and converted into a formulation-compatible conjugate.
Surface display is usually the decisive variable in a CPP-LNP program. We build a density series and evaluate it together with particle quality rather than selecting a single ratio by default.
Adding a cationic or amphipathic peptide changes the self-assembly environment. We optimize the core formulation and the CPP surface layer together, not as separate steps.
We generate the particle-level data needed to judge whether a CPP-LNP candidate is suitable for biological testing, and to make batch-to-batch comparison meaningful.
Increased association alone is not evidence of productive delivery. We design paired readouts so that uptake and function can be compared directly for the same formulation set.
Once a candidate formulation is selected, BOC Sciences supports process development so that the construct can be reproduced with comparable attributes.
Different CPP families solve different delivery problems. Cationic peptides favor membrane contact and adsorption-driven uptake, amphipathic peptides favor membrane insertion and endosomal destabilization, and engineered peptides address selectivity or escape. BOC Sciences helps clients select a starting family from the list below and then compare it against alternatives within the same targeted LNP development framework.
Oligoarginine peptides are the most direct cationic CPP option. The guanidinium group forms bidentate interactions with membrane phosphate and sulfate groups, which drives strong cell-surface association and internalization.
TAT(48–60), derived from the HIV-1 transactivator of transcription protein, is the most widely used reference CPP. It enters cells through both direct translocation and energy-dependent endocytic routes, and it is comparatively well tolerated among cationic peptides.
Penetratin corresponds to residues 43–58 of the Drosophila Antennapedia homeodomain. It is amphipathic and tryptophan-rich, and it inserts into the lipid bilayer rather than relying only on electrostatic adsorption.
Transportan and its shorter analogue TP10 are chimeric peptides combining a galanin-derived segment with a mastoparan-derived segment. They are more membrane-active than TAT or oligoarginine.
MPG was designed for oligonucleotide delivery and combines a hydrophobic fusion-peptide-derived segment with a hydrophilic cationic segment. MAP is an amphipathic helical peptide commonly used for peptide and protein cargo.
When a standard CPP improves uptake but reduces selectivity, engineered variants are often the better route. These designs keep the peptide relatively inactive until a local trigger is present.
The incorporation route determines how much of the peptide is actually accessible on the outer surface, how much payload is retained, and how reproducible the construct is. BOC Sciences selects the route from the payload sensitivity and the required density control, drawing on our nanoparticle conjugation services platform.
The CPP-lipid conjugate is included in the lipid phase and becomes part of the particle during self-assembly. This is the most direct route and is compatible with standard microfluidic and ethanol-dilution preparation.
Preformed LNPs are incubated with CPP-lipid micelles under controlled temperature so that the conjugate transfers into the outer leaflet of the particle.
A reactive handle is built into the LNP surface through a functionalized PEG-lipid, and the peptide is attached afterward through a defined chemical reaction under mild aqueous conditions.
Cationic or amphipathic peptides are adsorbed onto the particle surface through electrostatic and hydrophobic interaction, without forming a covalent bond.
Stronger Entry Into Hard-to-Transfect Cell Models
Many research models, including suspension cells, primary cells, neuronal cells, and differentiated epithelial models, take up standard LNPs poorly. A CPP surface layer increases membrane contact and internalization through both adsorptive and insertion-driven mechanisms. This can move a formulation from a barely detectable uptake signal into a workable range without changing the ionizable lipid or the payload.
A Route to Address the Endosomal Escape Bottleneck
For nucleic acid payloads, only a small fraction of internalized material typically reaches the cytosol, and this step often limits functional outcome more than uptake does. Amphipathic and pH-responsive CPPs can destabilize the endosomal membrane after acidification, which is why a CPP-LNP can improve functional readout even when the association gain looks modest. Measuring escape directly is what separates a real gain from an apparent one.
Sequence-Level Tunability
CPP behavior can be adjusted at the residue level: net charge, arginine-to-lysine ratio, hydrophobic face, histidine content, cyclization, terminal handle position, and spacer length. This design freedom lets a team trade uptake against selectivity, or uptake against escape, within one chemical class. Peptides also avoid the immunogenicity concerns associated with larger proteinaceous ligands and are straightforward to characterize analytically.
Compatibility With Established LNP Preparation
CPP-lipid conjugates can be introduced during co-assembly or by post-insertion, so existing microfluidic and ethanol-dilution workflows generally remain usable. Surface density is controlled through a molar ratio rather than through a new process step, which keeps screening and later batch preparation on the same platform and simplifies comparison against an unmodified parent LNP.
Each payload class places different demands on the CPP choice and on the incorporation route. BOC Sciences matches the peptide, the conjugation chemistry, and the formulation conditions to the payload rather than applying one fixed CPP recipe.
| Payload Type | Supported Uses & CPP-LNP Development Considerations | Request Information |
|---|---|---|
| CPP-LNP Development for siRNA | Suitable for gene-silencing studies in low-uptake cell models and for knockdown comparison against unmodified LNPs. Development focuses on encapsulation stability, free RNA reduction, CPP density, and paired uptake and knockdown readouts. Related work is described under lipid nanoparticles for siRNA delivery. | Inquiry |
| CPP-LNP Development for mRNA and Reporter RNA | Designed for reporter expression, protein expression, antigen-related delivery, and formulation comparison studies. Development considers mRNA integrity, encapsulation efficiency, CPP surface exposure, endosomal release, and expression readouts in the selected cell model; see lipid nanoparticles for mRNA delivery. | Inquiry |
| CPP-LNP Development for circRNA and Self-Amplifying RNA | Applicable to RNA systems that need strong payload protection and sustained expression. BOC Sciences supports lipid nanoparticles for circRNA delivery with CPP surface modification, including stability evaluation and cell-based expression testing. | Inquiry |
| CPP-LNP Development for CRISPR RNP and gRNA/mRNA | Supports ribonucleoprotein and co-loaded nucleic acid systems that need cytosolic or nuclear access and ratio control. We evaluate complexation stability, particle uniformity, CPP compatibility, and editing readouts under matched control conditions; see lipid nanoparticles for CRISPR RNP delivery. | Inquiry |
| CPP-LNP Development for Protein | Suitable for enzymes, antibodies, binding proteins, and functional protein payloads that must reach the cytosol. Work focuses on mild loading, aggregation control, activity retention, and CPP-dependent uptake; see LNP-based protein delivery. | Inquiry |
| CPP-LNP Development for Peptide | Designed for therapeutic peptides, antigenic peptides, and labeled peptide probes. Development addresses peptide-lipid compatibility, loading route, leakage control, and CPP density; see LNP-based peptide delivery. | Inquiry |
| CPP-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules used in intracellular delivery research. We consider drug-lipid compatibility, loading method, leakage control, particle stability, CPP modification, and release behavior; see lipid nanoparticles for small molecule delivery. | Inquiry |
| CPP-LNP Development for Fluorescent and Imaging | Supports fluorescent dyes, labeled RNA, labeled proteins, and other tracking payloads used to study CPP-LNP uptake, intracellular localization, endosomal escape, and formulation comparison. | Inquiry |
| CPP-LNP Development for Custom Payload | Developed for unusual payloads, multi-payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, CPP type and route, particle stability, and intracellular delivery performance. | Inquiry |
CPP-LNP projects usually fail for one of two reasons: the peptide raises association without improving cytosolic delivery, or the peptide destabilizes the particle before biology can be tested. BOC Sciences addresses both with data-guided formulation development.
✔ High Cellular Association but Weak Cytosolic Delivery
A CPP-LNP can show several-fold higher cell-associated fluorescence while reporter expression or knockdown barely changes. We separate the two steps by measuring colocalization with endosomal markers and a cytosolic-access readout alongside the functional endpoint, then switch the peptide class from purely cationic toward amphipathic or pH-responsive designs if escape is the limiting step.
✔ Particle Aggregation After Cationic CPP Conjugation
Oligoarginine and TAT can shift zeta potential from slightly negative to strongly positive, and particles that look stable in low-ionic-strength buffer may aggregate in saline or serum-containing medium. We screen density and PEG-lipid content together and confirm size and PDI in the actual assay medium, supported by our LNP zeta potential optimization services.
✔ Non-Specific Uptake and Poor Cell Selectivity
Classical CPPs enter nearly any cell they contact, which is a problem when the project needs differential uptake between two models. We address this with activatable designs carrying a cleavable masking domain, with CPP-targeting peptide fusions, or by pairing the CPP with a separate targeting ligand while lowering CPP density to the minimum useful level.
✔ Reduced Payload Encapsulation After Surface Modification
Introducing a charged peptide into the assembly environment can lower encapsulation efficiency or cause partial payload displacement. We rebalance lipid composition, aqueous phase pH, and payload-to-lipid ratio, and where appropriate switch to post-insertion or covalent coupling; see our work on nucleic acids encapsulation in LNPs.
✔ Serum Instability and Protein Corona Masking
A CPP-LNP that performs well in serum-free medium can lose most of its advantage once serum proteins adsorb onto the surface and cover the peptide. We compare performance in serum-free and serum-containing conditions, adjust spacer length to lift the peptide above the corona layer, and verify the finding with a matched unmodified control in the same medium.
✔ CPP Proteolysis and Short Surface Functional Lifetime
Linear peptides are exposed on the outer surface and can be cleaved by serum or cell-surface proteases, so the functional window may be shorter than the particle circulation window. We evaluate stability in the relevant medium and, where needed, propose cyclization, D-amino acid substitution, terminal capping, or sequence truncation as testable alternatives.
If you encounter challenges at any stage of CPP-LNP development, our experts are here to help. Share your specific challenges with BOC Sciences, and we will work with you to explore suitable solutions.
We review cargo properties, intended cell model, current formulation, desired mechanism, and functional acceptance criteria. This helps define a CPP shortlist, appropriate controls, and whether peptide modification is the most relevant strategy for the problem.
We synthesize selected CPP-lipid constructs or prepare reactive lipids, establish coupling routes, and formulate pilot LNPs. For process-sensitive cargo, we may compare direct co-assembly and postformation modification with matched CPP-free controls.
Through LNP process optimization, we screen peptide density, lipid composition, processing conditions, and purification. Candidate formulations are compared for size, PDI, charge, peptide association, payload loading, and relevant stability indicators.
We combine nanoparticle cellular uptake testing with localization and cargo-specific functional assays. We summarize which design variables influence activity and identify the candidate best aligned with the project's target readout.
CPP-conjugated LNPs are used where the limiting step is intracellular rather than tissue-level. BOC Sciences helps research teams build CPP-LNP systems for the following research directions, with the peptide and density chosen for each specific question.
Looking to develop CPP-LNPs for a specific molecular target, disease-related research application, or unique delivery need? BOC Sciences provides customized support in CPP design, peptide-lipid conjugate synthesis, LNP formulation, and functional delivery evaluation to help bring your research ideas to life.
Background and Challenge: A research team was developing an LNP carrier for a cytosolic enzyme of roughly 45 kDa in a difficult-to-transfect adherent cell model. Their parent LNP showed acceptable particle attributes, with an average size near 85 nm, a PDI around 0.12, and a zeta potential close to −8 mV, but the intracellular activity signal was close to background. The team asked BOC Sciences to add a polyarginine surface layer to increase cellular entry while keeping enzyme activity intact.
Diagnosis: Our first review showed that the limiting step was cellular entry, not endosomal release, so a cationic CPP was a reasonable starting point. The initial client-side attempt with a non-covalently adsorbed R9 peptide, however, had produced a mean size above 250 nm with a PDI near 0.40 and a zeta potential around +38 mV after incubation in phosphate-buffered saline, consistent with charge-driven aggregation rather than with peptide display.
Exploration: BOC Sciences built a structured panel rather than testing a single design. We compared four arginine lengths (R6, R8, R9, R11), two lipid anchors (CPP-PEG2000-DSPE and stearyl-CPP), and three surface densities (0.5, 1.5, and 3 mol%), giving 24 formulations prepared by post-insertion onto a common parent batch. Every candidate was checked for size and PDI in both low-ionic-strength buffer and serum-containing medium, then for conjugation level, enzyme loading, uptake, and cytosolic enzyme activity.
Result: The stearyl-anchored variants aggregated at 3 mol% in all media and were dropped. Among the PEG-spaced series, R8 at 1.5 mol% gave the best balance: mean size 92 nm, PDI 0.14, zeta potential around +12 mV, enzyme loading near 78%, and cell-associated signal approximately 4.2-fold higher than the unmodified parent LNP. Cytosolic enzyme activity increased about 3-fold over the parent formulation, and viability stayed above 90% at the tested dose. The shorter R6 variant gave less uptake, and R11 gave more association but lower activity, which supported selecting the middle arginine length.
Background and Challenge: A biotechnology group working on a reporter mRNA construct of about 1.1 kb had an LNP that already showed strong cellular association but weak luminescence output. Their in-house TAT-modified variant increased cell-associated signal by roughly 2-fold yet left reporter expression essentially unchanged, suggesting that the added peptide had improved entry without improving cytosolic release.
Diagnosis: We ran a paired evaluation and confirmed the client's suspicion: the TAT variant raised association while endosomal colocalization remained high, so the construct was accumulating in the endosomal compartment. Increasing TAT density further would likely have raised uptake without addressing escape, and would have pushed zeta potential into a range where serum stability becomes a concern.
Exploration: BOC Sciences screened five peptide designs against the same parent LNP: TAT(48–60), penetratin, TP10, MPG, and a histidine-enriched TAT variant designed to become membrane-active after endosomal acidification. Each peptide was attached by thiol-maleimide coupling through a terminal cysteine, with the maleimide-functionalized PEG-lipid substituted at 10%, 30%, or 50% of the total PEG-lipid fraction, giving 15 candidates. Particle attributes, encapsulation efficiency, mRNA integrity, association, endosomal colocalization, and reporter expression were measured for the full set.
Result: TP10 produced the largest association gain, around 3.4-fold, but viability fell below 80% at the tested dose and the candidate was set aside. Penetratin and MPG gave intermediate results. The histidine-enriched TAT variant at 30% substitution performed best: mean size 78 nm, PDI 0.12, zeta potential around −4 mV, encapsulation efficiency near 91%, association about 2.3-fold over the unmodified parent, and reporter expression roughly 9-fold higher. The client received a formulation direction in which escape, not uptake, was the optimized variable, along with the control data needed to support that interpretation.
Broad CPP Library and Custom Sequence DesignWe help investigate established CPP families and tailor sequence, terminal groups, spacer chemistry, and modifications for the intended cell and cargo model.
Controlled Peptide Conjugation and Surface EngineeringOur nanoparticle conjugation services support rational comparison of peptide attachment route, linker architecture, conjugation efficiency, and surface-accessible ligand density.
Comprehensive Physicochemical and Functional CharacterizationWe connect particle and surface measurements with uptake, intracellular localization, functional payload assays, and controls needed to interpret CPP performance.
Payload-Specific Formulation OptimizationCPP selection and LNP composition are coordinated for RNA, proteins, peptides, gene-editing components, small molecules, and labeled research cargo.
Flexible Custom Development and Process SupportWe support proof-of-concept screening, comparative formulation studies, peptide conjugation troubleshooting, preparation refinement, and repeat-batch evaluation aligned with the project question.
Cell-penetrating peptide-conjugated lipid nanoparticles (CPP-LNPs) incorporate membrane-interacting peptides onto the nanoparticle surface to promote cellular association and internalization. Depending on peptide sequence, charge, amphipathicity, and surface density, CPPs may interact with cell membranes and influence endocytic uptake pathways. Common CPPs include polyarginine, TAT-derived peptides, penetratin, and transportan derivatives. However, increased cellular uptake does not necessarily indicate improved cytosolic delivery, as internalized nanoparticles may remain trapped within endosomes. Effective CPP-LNP development therefore requires coordinated optimization of peptide presentation, lipid composition, colloidal stability, and intracellular trafficking. Functional delivery should be confirmed through payload-specific measurements, such as protein activity, mRNA expression, or siRNA-mediated gene silencing.
Common CPP candidates for lipid nanoparticle modification include polyarginine peptides (R8, R9, R11), TAT-derived peptides, penetratin, transportan/TP10, and amphipathic peptides such as MPG and MAP. Polyarginine and TAT-derived sequences provide cationic membrane interactions, while penetratin and amphipathic CPPs offer different combinations of electrostatic and hydrophobic interactions. Peptide selection depends on the intended payload, target cell model, conjugation chemistry, and intracellular delivery requirements. Highly cationic peptides may increase nonspecific cellular association or particle aggregation, whereas amphipathic sequences may require additional evaluation of membrane compatibility. Researchers should compare peptide candidates using matched LNP formulations and assess surface accessibility, serum stability, cellular uptake, endosomal trafficking, and functional payload activity before selecting a final design.
CPP-modified lipid nanoparticles may produce strong cellular fluorescence signals without delivering sufficient functional payload into the cytosol. This occurs because measured fluorescence can represent cell-surface attachment, endosomal accumulation, or intracellularly retained carrier material rather than released cargo. Some CPP structures promote cellular internalization but do not provide efficient endosomal escape under the conditions tested. Researchers should therefore combine flow cytometry with surface-binding controls, confocal microscopy, endosomal colocalization analysis, and payload-specific functional assays. For example, mRNA delivery can be evaluated through reporter protein expression, while protein delivery may require measurements of intracellular enzymatic activity. Comparing these results with unmodified LNP controls helps distinguish increased cellular association from meaningful improvements in intracellular payload availability.
Yes. BOC Sciences provides customized CPP-conjugated LNP development services for nucleic acids, proteins, peptides, small molecules, imaging probes, and selected gene-editing components. Our development strategy considers the physicochemical properties of each payload, including molecular size, charge, solubility, structural stability, and required intracellular localization. We support CPP sequence selection, peptide-lipid conjugate design, surface functionalization, formulation screening, and payload encapsulation optimization. For protein delivery projects, particular attention is given to preserving protein conformation and biological activity. For RNA payloads, we evaluate encapsulation, molecular integrity, and functional expression or silencing. Formulation candidates can also be compared through particle characterization, cellular uptake measurements, and relevant functional assays to identify suitable development directions.
BOC Sciences supports systematic troubleshooting of CPP-LNP development challenges, including particle aggregation, excessive positive surface charge, reduced payload encapsulation, unstable peptide presentation, serum-induced performance changes, and insufficient cytosolic delivery. Our approach begins by examining CPP sequence properties, peptide-lipid conjugation chemistry, ligand density, and the composition of the underlying LNP formulation. We then evaluate relevant parameters such as particle size, polydispersity index, zeta potential, payload retention, and peptide surface accessibility. When necessary, we compare different CPP structures, spacer lengths, incorporation strategies, and lipid compositions. Cell-based evaluations help determine whether observed changes improve cellular uptake, intracellular trafficking, and functional payload delivery. This integrated approach supports evidence-based formulation selection and improved preparation reproducibility.
